Exercise of options and total voting rights

About this update from Abingdon Health Plc

  This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.     Abingdon Health plc ("Abingdon Health", the "Group" or the "Company")   Exercise of options and total voting rights   York, U.K.  29 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces that it has applied for 5,208 new ordinary shares of 0.025 pence each ("Ordinary Shares") in the Company to be admitted to trading on AIM on 30 December 2025 following an exercise of share options.   Following the issue of the 5,208 new Ordinary Shares the Company will have a total of 251,077,850 Ordinary Shares in issue. The Company does not hold any shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules.   Enquiries:   Abingdon Health plc www.abingdonhealth.com/investors/ Chris Hand, Executive   Chairman   Via Walbrook PR T om Hayes, CFO   Zeus (Sole Broker and Nominated Adviser)   Tel:  +44 (0)20 3829 5000 Antonio Bossi / Jacob Walker (Corporate Finance)         Walbrook PR (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or  [email protected] Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654     About Abingdon Health   Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.      The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.    Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK.  Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.    Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.   Abingdon Health's  brochure  outlines the comprehensive support the Group can now provide to its international customers.  For more information visit:  www.abingdonhealth.com .  

View stock analysis, news, and events for Abingdon Health Plc